Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders, has entered a broad, multi-year manufacturing agreement with CordenPharma, a CDMO covering the active pharmaceutical ingredient (API) and final finished product supply for its VK2735 program for obesity.  The agreement provides Viking with a sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential mult...